Sanofi Secures European Approval for Multiple Sclerosis Drug, Japan Clearance for Immune Disease Drug

MT Newswires Live06-23

Sanofi's (SNY) treatment for multiple sclerosis has been approved in Europe, while a therapy for immune thrombocytopenia has been cleared in Japan, the company said Tuesday.

Cenrifki has been approved in the European Union as a treatment for secondary progressive multiple sclerosis without relapses, the company said.

The approval was based on phase 3 studies showing the drug "significantly delayed" disability progression with a consistent safety profile, the company said.

Sanofi plans to make Cenrifki available in Germany in 2026.

In a separate statement, Sanofi said Japan approved Wayrilz to treat immune thrombocytopenia in patients who do not respond sufficiently to or cannot tolerate other treatments.

The approval was supported by a phase 3 study showing rapid and durable platelet responses and improvements in other symptoms, Sanofi said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment